Posted by Michael Wonder on 05 May 2022
Novartis receives European Commission approval for Jakavi to be the first post-steroid treatment for acute and chronic graft versus host disease
5 May 2022 - Jakavi is the first JAK1/2 inhibitor available for patients in Europe who previously had no approved therapies for the treatment of steroid refractory graft versus host disease.
Novartis today announced the European Commission has approved Jakavi (ruxolitinib) for the treatment of patients aged 12 years and older with acute or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies.
